Advertisement


Luca Gianni, MD, on Locally Advanced, HER2-Positive Breast Cancer: New Data on Neoadjuvant Therapy and Atezolizumab

2023 SABCS

Advertisement

Luca Gianni, MD, of Milan’s Fondazione Michelangelo, discusses findings from the APTneo Michelangelo trial, which showed that adding atezolizumab to chemotherapy and trastuzumab plus pertuzumab did not significantly increase the rate of pathologic complete response (pCR) in women with HER2-positive breast cancer. An exploratory analysis showed that adding atezolizumab to neoadjuvant anthracycline and cyclophosphamide followed by HPCT (trastuzumab + pertuzumab and chemotherapy) led to higher pCR rates than HPCT and atezolizumab (Abstract LBO1-02).



Related Videos

Breast Cancer

Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine

Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases) (Abstract GS01-10).

Breast Cancer

Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with early-stage, high-risk ER-positive or HER2-negative breast cancer (Abstract GS01-02).

Breast Cancer

Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer (Abstract GS03-03).

Breast Cancer

Eleftherios P. Mamounas, MD, on Locoregional Irradiation, Axillary Lymph Node Involvement, and Conversion to Negative Nodes

Eleftherios P. Mamounas, MD, of Orlando Health Cancer Institute, discusses primary outcomes from the NRG Oncology/NSABP B-51/RTOG 1304 study of locoregional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy (Abstract GS02-07).

Breast Cancer

Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel

Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses recent data showing that for patients with stage I/II triple-negative breast cancer, 12 weeks of a neoadjuvant nonanthracycline chemotherapy regimen with nivolumab may be efficacious with either concurrent or lead-in nivolumab. Those with immune-enriched tumors had high pathologic complete response rates, identifying a subpopulation for whom a 12-week anthracycline-free chemotherapy regimen with nivolumab may be appropriate (Abstract LBO1-03).

Advertisement

Advertisement




Advertisement